A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify) Meeting Abstract
| Authors: | Daver, N. G.; Maiti, A.; Sallman, D. A.; Roboz, G. J.; Solh, M. M.; Milano, F.; Strickland, S. A.; Eghtedar, A.; Kanner, S. B.; Ledergor, G.; Marcy, D.; Garner, E.; Francica, B. J.; Shaw, M.; Bird, K.; Rattan, J.; Zudaire, E.; Portella, S.; Vachhani, P.; Park, J. H. |
| Abstract Title: | A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406324 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS6586 |
| Notes: | Meeting Abstract: TPS6586 -- Source: Wos |
